<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949024</url>
  </required_header>
  <id_info>
    <org_study_id>CLS1004-101</org_study_id>
    <nct_id>NCT02949024</nct_id>
    <nct_alias>NCT02944240</nct_alias>
  </id_info>
  <brief_title>Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema</brief_title>
  <acronym>HULK</acronym>
  <official_title>Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clearside Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clearside Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA
      alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema
      associated with diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, multicenter, open-label study in subject with DME associated with
      diabetes mellitus.

      Subjects will be screened and if eligible, will be assigned to study arm at the Baseline
      Visit (Visit 1, Day 0).

      Following the Baseline Visit, subjects will participate in six month follow-up visits (Visit
      2-7; Weeks 4-24) for safety and efficacy assessments and to determine whether additional
      therapy is needed based upon established criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">April 12, 2017</completion_date>
  <primary_completion_date type="Actual">April 12, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events and serious adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Grouped by organ system, relatedness to study treatment and severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in intraocular pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by applanation tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in central subfield thickness</measure>
    <time_frame>6 months</time_frame>
    <description>Based on spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Based on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLS-TA injections</measure>
    <time_frame>6 months</time_frame>
    <description>Number of injections of CLS-TA administered</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>TX Naïve Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previous TX Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVT aflibercept + SC CLS-TA</intervention_name>
    <description>IVT aflibercept [2 mg (50 µL)] + SC CLS-TA [4 mg (100 µL)]</description>
    <arm_group_label>TX Naïve Arm</arm_group_label>
    <other_name>Triamcinolone Acetonide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC CLS-TA</intervention_name>
    <description>[4 mg (100 µL)]</description>
    <arm_group_label>Previous TX Arm</arm_group_label>
    <other_name>Triamcinolone Acetonide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ≥ 18 years of age with type 1 or type 2 diabetes mellitus

          -  DME with central involvement in the study eye

          -  ETDRS BCVA letter score of 83 to 14, inclusive (Snellen equivalent of 20/25 to 20/500)
             in the study eye

        Exclusion Criteria:

          -  Intraocular pressure ≥ 22 mmHg or uncontrolled glaucoma (open angle or angle closure)
             in the study eye

          -  History of any previous ophthalmic surgeries in the study eye within 90 days of
             screening

          -  Subjects previously treated for DME cannot have been treated in the study eye with an
             intravitreal injection of anti-VEGF or periocular corticosteroids within 90 days prior
             to screening (Previous TX arm only)

          -  Subjects previously treated for DME cannot have been treated in the study eye with
             intraocular corticosteroids within 6 months prior to screening (Previous TX arm only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Kissner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clearside Biomedical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <disposition_first_submitted>May 7, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 7, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 9, 2018</disposition_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Microneedle</keyword>
  <keyword>Microinjection</keyword>
  <keyword>Triamcinolone</keyword>
  <keyword>Choroid</keyword>
  <keyword>Choroid Injection</keyword>
  <keyword>Aflibercept</keyword>
  <keyword>Suprachoroidal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

